Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kineret Could Bring Earlier Remission in Still’s Disease: Expert
The launch of Swedish Orphan Biovitrum Japan’s (Sobi Japan) IL-1 receptor antagonist Kineret (anakinra) could make earlier remission a realistic goal for patients with Still’s disease, a Japanese expert says. “With Kineret, early remission of Still’s disease is becoming a…
To read the full story
Related Article
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
BUSINESS
- Lenvima-Welireg Combo Gets US Nod for Advanced RCC
September 28, 2026
- Daiichi Sankyo Pulls US Filing for B7-H3 ADC in SCLC
September 28, 2026
- Narcolepsy Diagnosis Still Takes Nearly 9 Years in Japan: Expert
September 28, 2026
- Japan OTC Market Down for 6th Straight Month in August: Intage
September 28, 2026
- IHH Unit Appeals Dismissal of 203 Billion Yen Daiichi Sankyo Suit
September 28, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…